Moderna (NASDAQ:MRNA) Rating Reiterated by Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Moderna (NASDAQ:MRNA) in a report released on Thursday morning, Benzinga reports. They currently have a $214.00 target price on the stock.

MRNA has been the topic of several other research reports. Oppenheimer increased their price objective on Moderna from $163.00 to $179.00 and gave the stock an outperform rating in a research report on Wednesday, June 12th. Evercore ISI reaffirmed an in-line rating and set a $120.00 price target on shares of Moderna in a research report on Thursday. UBS Group boosted their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a buy rating in a report on Tuesday, May 7th. Royal Bank of Canada raised their target price on shares of Moderna from $135.00 to $160.00 and gave the stock an outperform rating in a report on Monday, June 3rd. Finally, Jefferies Financial Group reiterated a buy rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of Hold and an average target price of $134.02.

Moderna Stock Performance

Shares of MRNA stock opened at $118.75 on Thursday. Moderna has a 52 week low of $62.55 and a 52 week high of $170.47. The company has a market capitalization of $45.51 billion, a price-to-earnings ratio of -7.58 and a beta of 1.54. The company has a 50-day simple moving average of $134.13 and a 200 day simple moving average of $112.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s revenue was down 91.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.19 earnings per share. On average, sell-side analysts predict that Moderna will post -7.46 earnings per share for the current year.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $210,561.12. Following the completion of the transaction, the insider now directly owns 10,623 shares in the company, valued at approximately $1,725,918.81. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $210,561.12. Following the completion of the transaction, the insider now directly owns 10,623 shares of the company’s stock, valued at approximately $1,725,918.81. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 411,255 shares of company stock valued at $56,118,931. 15.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the fourth quarter worth $27,000. Cedar Wealth Management LLC lifted its holdings in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares during the period. Arlington Trust Co LLC grew its position in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in shares of Moderna in the first quarter valued at about $32,000. Finally, Rise Advisors LLC raised its position in shares of Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.